Press Release / Health and Fitness / Bacteriostatic Antibiotics Market Growth Analysis Till 2026

Bacteriostatic Antibiotics Market Growth Analysis Till 2026

Antibiotics are naturally occurring or artificially produced substances, which are widely used in the treatment of bacterial diseases. Antibiotics works by killing bacteria (bactericidal effect) or by inhibiting their growth (bacteriostatic effect). Although bacteriostatic antibiotics prevent bacterial growth and reproduction, it does not necessarily kill them.

Download PDF Brochure of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-pdf/2307

Bacteriostatic Antibiotics Market Drivers

Global bacteriostatic antibiotics market is expected to witness a significant growth over the forecast period, owing to recent approval and launch of novel bacteriostatic antibiotics products in the market.

For instance, in September 2018, Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company dedicated to development, manufacturing, and commercialization of novel antibiotics for treat life-threatening multidrug-resistant (MDR) infections received European Commission (EC) marketing authorization for its novel bacteriostatic antibiotic namely XERAVA (eravacycline) injection, which is indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults in the European Union. XERAVA (Eravacycline) is a fluorocycline antibacterial within the tetracycline class of antibacterial drugs, it is bacteriostatic against gram-positive bacteria (e.g., Staphylococcus aureus and Enterococcus faecalis)

Furthermore, high prevalence of bacterial and infectious disease is expected to propel demand for bacteriostatic antibiotics, in turn driving global bacteriostatic antibiotics market growth.

Bacteriostatic Antibiotics Market Regional Analysis

North America bacteriostatic antibiotics market is expected to hold a dominant position in the global Bacteriostatic Antibiotics Market and account for largest market share over the forecast period, owing to presence of key players and approval and launch of novel bacteriostatic antibiotics drugs by them in the region.

For instance, in August 2018, Tetraphase Pharmaceuticals, Inc., a Massachusetts, U.S-based biopharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for its novel bacteriostatic antibiotics namely XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections (cIAI)

Bacteriostatic Antibiotics Market Key Players

Key players operating in global Bacteriostatic Antibiotics Market include Tetraphase Pharmaceuticals, Inc., Allergan Plc., Pfizer Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals Plc., Akorn Inc., and Others.

Request A Sample Copy of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2307

Bacteriostatic Antibiotics Market Taxonomy:

The global bacteriostatic antibiotics market is segmented on the basis of indication, age group, dosage form, distribution channel, and region

By Type-

Tetracycline
Doxycycline
Chloramphenicol
Erythromycin
Fusidic acid
Sulfonamides
Trimethoprim
Macrolides
Lincosamides
Others
By Age Group

Pediatric
Adults
By Dosage Form-

Tablet
Capsule
Injectables
By Distribution Channel-

Hospitals Pharmacies
Retail Pharmacies
Online pharmacies
About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com